Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment for newly diagnosed glioblastomas currently involves surgical resection followed by Temozolomide chemotherapy with concomitant radiotherapy, and then 6 cycles of Temozolomide in adjuvant. According to many studies, only those patients not expressing the enzyme repair MGMT benefit from the adjunction of Temozolomide. Therefore, many patients receive unnecessary treatment. The aim of this project is to compare different techniques for analysis of MGMT in order to choose the approach with the best cost/utility ratio, which will allow the selection of patients likely to respond to TMZ chemotherapy during the first course of GBM treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Center Eugene Marquis
• Collaborator: Rennes University Hospital
• Treatments: Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• Adult, age from 18 to 70

• Pre-surgical diagnosis compatible with a primary or secondary sub-tentorial glioblastoma than can be resected

• No counter-indication to an adjuvant treatment according to the Stupp schedule

• Free written informed consent

Exclusion Criteria:

• Absence of tumor sample available

• Definite histology not related to a glioblastoma or a main oligodendroglioma component